Hawe E, McBride D, Balp MM, Tian H, Halliday A, Stull DE. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics. 2016 May;34(5):521-7. doi: 10.1007/s40273-015-0375-7
Hawe E, Stull DE, McBride D, Balp MM. Improvement in quality of life (QOL) of patients with refractory chronic spontaneous/idiopathic urticaria (CSU/CIU) as assessed by the EURO-QOL (EQ-5D). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.
Hawe E, Vickers AD, Mallya UG, McBride DW, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2014. Amsterdam, the Netherlands.